These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

788 related items for PubMed ID: 15533851

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A.
    Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Race-based therapeutics.
    Bloche MG.
    N Engl J Med; 2004 Nov 11; 351(20):2035-7. PubMed ID: 15533852
    [No Abstract] [Full Text] [Related]

  • 25. Have we witnessed the rise and fall of race-specific drugs?
    Coons SJ.
    Clin Ther; 2009 Mar 11; 31(3):620-2. PubMed ID: 19393852
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Dilemmas With Race and Heart Failure Treatment.
    Butler J, Konstam MA.
    Circ Heart Fail; 2016 Oct 11; 9(10):. PubMed ID: 27707751
    [No Abstract] [Full Text] [Related]

  • 28. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.
    Johnson G, Carson P, Francis GS, Cohn JN.
    Circulation; 1993 Jun 11; 87(6 Suppl):VI32-9. PubMed ID: 8500237
    [Abstract] [Full Text] [Related]

  • 29. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.
    Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, Ofili E, Ferdinand K, Loscalzo J, Worcel M, A-HeFT Investigators.
    J Card Fail; 2002 Jun 11; 8(3):128-35. PubMed ID: 12140804
    [Abstract] [Full Text] [Related]

  • 30. Race and a heart drug.
    Peota C.
    Minn Med; 2005 Mar 11; 88(3):11. PubMed ID: 15852585
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. BiDil for heart failure.
    Med Lett Drugs Ther; 2005 Sep 26; 47(1218):77-8. PubMed ID: 16186789
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. FDA approves heart drug for black patients.
    Meadows M.
    FDA Consum; 2005 Sep 26; 39(5):8-9. PubMed ID: 16419285
    [Abstract] [Full Text] [Related]

  • 36. Effect of vasodilator therapy on mortality in chronic congestive heart failure.
    Ghose JC, Chakraborty S, Mondal M, Bhandari B.
    J Assoc Physicians India; 1993 May 26; 41(5):269-71. PubMed ID: 8300456
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure.
    Angus DC, Linde-Zwirble WT, Tam SW, Ghali JK, Sabolinski ML, Villagra VG, Winkelmayer WC, Worcel M, African-American Heart Failure Trial (A-HeFT) Investigators.
    Circulation; 2005 Dec 13; 112(24):3745-53. PubMed ID: 16344404
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.
    Temple R, Stockbridge NL.
    Ann Intern Med; 2007 Jan 02; 146(1):57-62. PubMed ID: 17200223
    [Abstract] [Full Text] [Related]

  • 40. Race, drugs, and heart failure.
    Aronow WS.
    Geriatrics; 2005 Jul 02; 60(7):8-9. PubMed ID: 16026175
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.